The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis
Open accessAbstract
BACKGROUND: Angiomyolipomas in patients with the tuberous sclerosis complex or sporadic lymphangioleiomyomatosis are associated with mutations in tuberous sclerosis genes resulting in constitutive activation of the mammalian target of rapamycin (mTOR). The drug sirolimus suppresses mTOR signaling. METHODS: We conducted a 24-month, nonrandomized, open-label trial to determine whether sirolimus reduces the angiomyolipoma volume in patients with the tuberous sclerosis complex or sporadic lymphangioleiomyomatosis. Sirolimus was administered for the first 12 months only. Serial magnetic resonance imaging of angiomyolipomas and brain lesions, computed tomography of lung cysts, and pulmonary-function tests were performed. RESULTS: Of the 25 patients enrolled, 20 completed the 12-month evaluation, and 18 completed the 24-month evaluation. The mean (+/-SD) angiomyolipoma volume at 12 months was 53.2+/-26.6% of the baseline value (P<0.001) and at 24 months was 85.9+/-28.5% of the baseline value (P=0.005). At 24 months, five patients had a persistent reduction in the angiomyolipoma volume of 30% or more. During the period of sirolimus therapy, among patients with lymphangioleiomyomatosis, the mean forced expiratory volume in 1 second (FEV1) increased by 118+/-330 ml (P=0.06), the forced vital capacity (FVC) increased by 390+/-570 ml (P<0.001), and the residual volume decreased by 439+/-493 ml (P=0.02), as compared with baseline values. One year after sirolimus was discontinued, the FEV1 was 62+/-411 ml above the baseline value, the FVC was 346+/-712 ml above the baseline value, and the residual volume was 333+/-570 ml below the baseline value; cerebral lesions were unchanged. Five patients had six serious adverse events while receiving sirolimus, including diarrhea, pyelonephritis, stomatitis, and respiratory infections. CONCLUSIONS: Angiomyolipomas regressed somewhat during sirolimus therapy but tended to increase in volume after the therapy was stopped. Some patients with lymphangioleiomyomatosis had improvement in spirometric measurements and gas trapping that persisted after treatment. Suppression of mTOR signaling might constitute an ameliorative treatment in patients with the tuberous sclerosis complex or sporadic lymphangioleiomyomatosis. (ClinicalTrials.gov number, NCT00457808.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Standardization of Spirometry, 1994 Update. American Thoracic Society.
(1995) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.152.3.7663792 · Cited by 6,594
TOR signaling in growth and metabolism
Wullschleger, S., Loewith, R., & Hall, M. N. (2006) · Cell · doi:10.1016/j.cell.2006.01.016 · Cited by 5,787
The tor pathway: a target for cancer therapy
Bjornsti, M.-A., & Houghton, P. J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1362 · Cited by 1,314
Dysregulation of the TSC-mTOR pathway in human disease
Inoki, K., Corradetti, M. N., & Guan, K.-L. (2005) · Nature Genetics · doi:10.1038/ng1494 · Cited by 972
Groth, C. G., Bäckman, L., Morales, J.-M., Calne, R., Kreis, H., Lang, P., Touraine, J.-L., Claesson, K., Campistol, J. M., Durand, D., et al. (1999) · Transplantation · doi:10.1097/00007890-199904150-00017 · Cited by 878
Galanis, E., Buckner, J. C., Maurer, M. J., Kreisberg, J. I., Ballman, K., Boni, J., Peralba, J. M., Jenkins, R. B., Dakhil, S. R., Morton, R. F., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.622 · Cited by 694
Kwiatkowski, D. J. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.5.525 · Cited by 667
Carsillo, T., Astrinidis, A., & Henske, E. P. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.11.6085 · Cited by 646
mTOR-targeted therapy of cancer with rapamycin derivatives
Vignot, S., Faivre, S., Aguirre, D., & Raymond, E. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi113 · Cited by 617
Rapamycin causes regression of astrocytomas in tuberous sclerosis complex
Franz, D. N., Leonard, J., Tudor, C., Chuck, G., Care, M., Sethuraman, G., Dinopoulos, A., Thomas, G., & Crone, K. R. (2006) · Annals of Neurology · doi:10.1002/ana.20784 · Cited by 614
Self-citationCauses of Death in Patients With Tuberous Sclerosis
SHEPHERD, C. W., GOMEZ, M. R., LIE, J. T., & CROWSON, C. S. (1991) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(12)61196-3 · Cited by 555
The NHLBI Lymphangioleiomyomatosis Registry: Characteristics of 230 Patients at Enrollment
Ryu, J. H., Moss, J., Beck, G. J., Lee, J.-C., Brown, K. K., Chapman, J. T., Finlay, G. A., Olson, E. J., Ruoss, S. J., Maurer, J. R., et al. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200409-1298oc · Cited by 468
Self-citationChapman, A. B., Guay-Woodford, L. M., Grantham, J. J., Torres, V. E., Bae, K. T., Baumgarten, D. A., Kenney, P. J., King, B. F., Glockner, J. F., Wetzel, L. H., et al. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00185.x · Cited by 413
Measuring Response in Solid Tumors: Unidimensional Versus Bidimensional Measurement
James, K., Eisenhauer, E., Christian, M., Terenziani, M., Vena, D., Muldal, A., & Therasse, P. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.6.523 · Cited by 401
ATS statement on six-minute walk test
Brooks, D., & Solway, S. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.167.9.950 · Cited by 352
Bissler, J. J., & Kingswood, J. C. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00838.x · Cited by 303
Self-citationKenerson, H. L., Aicher, L. D., True, L. D., & Yeung, R. S. W. (2002) · PubMed · Cited by 290
FRANZ, D. N., BRODY, A., MEYER, C., LEONARD, J., CHUCK, G., DABORA, S., SETHURAMAN, G., COLBY, T. V., KWIATKOWSKI, D. J., & Mc CORMACK, F. X. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.164.4.2011025 · Cited by 287
Self-citationDiagnosis of Tuberous Sclerosis Complex
Roach, E. S., & Sparagana, S. P. (2004) · Journal of Child Neurology · doi:10.1177/08830738040190090301 · Cited by 281
Recurrent Lymphangiomyomatosis after Transplantation: Genetic Analyses Reveal a Metastatic Mechanism
Karbowniczek, M., Astrinidis, A., Balsara, B. R., Testa, J. R., Lium, J. H., Colby, T. V., McCormack, F. X., & Henske, E. P. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200208-969oc · Cited by 254
Self-citationTaveira-DaSilva, A. M., Stylianou, M. P., Hedin, C. J., Hathaway, O., & Moss, J. (2004) · Chest · doi:10.1378/chest.126.6.1867 · Cited by 237
National Institutes of Health Consensus Conference: Tuberous Sclerosis Complex
Hyman, M. H., & Whittemore, V. H. (2000) · Archives of Neurology · doi:10.1001/archneur.57.5.662 · Cited by 195
Renal angiomyolipoma: optimal treatment based on size and symptoms.
Dickinson, M., Ruckle, H. C., Beaghler, M. A., & Hadley, H. R. (1998) · PubMed · Cited by 173
Hong, J. C., & Kahan, B. D. (2000) · Transplantation · doi:10.1097/00007890-200005270-00019 · Cited by 162
Taveira‐DaSilva, A. M., Steagall, W. K., & Moss, J. (2006) · Cancer Control · doi:10.1177/107327480601300405 · Cited by 127
Antitumoral Activity of Rapamycin in Renal Angiomyolipoma Associated With Tuberous Sclerosis Complex
Wienecke, R., Fackler, I., Linsenmaier, U., Mayer, K., Licht, T., & Kretzler, M. (2006) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2006.05.018 · Cited by 118
Delayed Wound Healing with Sirolimus after Liver Transplant
Guilbeau, J. M. (2002) · Annals of Pharmacotherapy · doi:10.1345/aph.1a128 · Cited by 86
Dramatic effect of sirolimus on renal angiomyolipomas in a patient with tuberous sclerosis complex
Herry, I., Neukirch, C., Debray, M., Mignon, F., & Crestani, B. (2007) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2006.07.017 · Cited by 75
Hypertriglyceridemia in renal transplant recipients treated with sirolimus
Brattström, C., Wilczek, H., Tydén, G., Böttiger, Y., Säwe, J., & Groth, C. G. (1998) · Transplantation Proceedings · doi:10.1016/s0041-1345(98)01301-3 · Cited by 54
Correlation of three-dimensional tumor volumetry with cervical cancer prognostic parameters.
Chen, A. C. Y., Sung, W. H., Wang, P. H., Sheu, M. H., Doong, J. L., & Yuan, C. (2002) · PubMed · Cited by 21
Cited by
The PI3K Pathway in Human Disease
Fruman, D. A., Chiu, H., Hopkins, B. D., Bagrodia, S., Cantley, L. C., & Abraham, R. T. (2017) · Cell · doi:10.1016/j.cell.2017.07.029 · Cited by 2,749
The LKB1-AMPK pathway: metabolism and growth control in tumour suppression
Shackelford, D. B., & Shaw, R. J. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2676 · Cited by 1,943
PI3K and cancer: lessons, challenges and opportunities
Fruman, D. A., & Rommel, C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4204 · Cited by 1,709
Northrup, H., Krueger, D. A., Northrup, H., Krueger, D. A., Roberds, S., Smith, K., Sampson, J., Korf, B., Kwiatkowski, D. J., Mowat, D., et al. (2013) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2013.08.001 · Cited by 1,502
Self-citationRapamycin: one drug, many effects
Li, J., Kim, S. G., & Blenis, J. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.01.001 · Cited by 1,287
Metadata
- Authors
- Bissler, J. J., McCormack, F. X., Young, L. R., Elwing, J. M., Chuck, G., Leonard, J. M., Schmithorst, V. J., Laor, T., Brody, A. S., Bean, J., Salisbury, S., & Franz, D. N.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-01-10
- Volume
- 358
- Issue
- 2
- Pages
- 140-151
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2050790870
- Cited by
- 1,253
- References
- 30
- FWCI
- 68.36
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.